Anatomical Distribution and Prevalence of Dysplasia in Sessile Serrated Lesions: A Cohort Study Over Seven Years Authors: Natalie Dierick, Michael Wu, Christina Lee, Simon Palfreeman, Bethan Butler, Stuart Kostalas Published: 2026 ABSTRACT Background and AimsSessile serrated lesions (SSLs) progress to colorectal cancer via a critical intermediary stage, SSL with dysplasia (SSLd). Data on the anatomical distribution of SSLd are limited, particularly in high-detection-rate settings. This study aimed to assess the prevalence and anatomical distribution of dysplasia in SSLs from a single-endoscopist practice with a consistently high SSL detection rate over 7 years.MethodsA retrospective analysis was conducted on all SSLs submitted to private pathology from a single endoscopist at Port Macquarie, Australia, between January 2019 and December 2025. Pathology reports were systematically reviewed, and terminology was standardized according to the 2019 World Health Organization Classification of Tumours of the Digestive System. Dysplasia was classified as a binary variable (present or absent) and attributed specifically to the SSL component. All specimens initially identified as SSLd were presented at the institutional histopathology meeting for review and reclassified where appropriate.ResultsA total of 3570 SSLs were identified across 2701 colonoscopy episodes. On initial pathology reporting, 102 SSLs were identified as harboring dysplasia (2.86%). After histopathology meeting review, 9 were reclassified (collision-type lesions of separate tubular adenoma and SSL in 3 cases, no dysplasia on review in 3 cases, traditional serrated adenoma in 2 cases, and conventional adenoma with a serrated growth pattern in 1 case), leaving 93 confirmed SSLd (2.61%). The confirmed dysplasia rate did not differ significantly between proximal (52/2114; 2.46%) and distal (25/824; 3.03%) colonic locations (P = .46). No individual anatomical site demonstrated a significantly different dysplasia rate. Colonoscopy episodes containing dysplastic SSLs had a higher mean number of synchronous SSLs compared to non-dysplastic episodes (1.6 vs 1.3; P = .005).ConclusionIn a large single-endoscopist pathology cohort, 2.61% of SSLs harbored confirmed cytological dysplasia after histopathology review. The reclassification rate of 8.8% was lower than the 33.3% reported in a prospective study with formal dual-expert pathologist review, though the pattern of reclassification was similar. Dysplasia was distributed throughout the colorectum without a significant proximal-distal predilection. Introduction Sessile serrated lesions (SSLs) are the most common polyp type that gives rise to carcinomas via the serrated neoplasia pathway and account for an estimated 25%–30% of all colorectal cancers (CRCs).1, 2, 3 These lesions progress to malignancy through a critical intermediary step, SSL with cytological dysplasia (SSLd), driven by an oncogenic BRAF mutation, progressive CpG island methylation, and eventual epigenetic silencing of DNA mismatch repair genes.2, 3, 4 Given their established malignant potential, identification and complete resection of SSLs are essential components of CRC prevention.5 SSLd is thought to have a short dwell time before rapid progression to overt carcinoma, making it rarely encountered at colonoscopy. This biological behavior has important clinical implications: SSLd represents a narrow window of opportunity for cancer prevention, and its detection is critically dependent on both endoscopic recognition and accurate histopathological diagnosis. In retrospective pathology series, only 2%–5% of SSLs have been found to harbor cytological dysplasia.6, 7, 8 However, in a large prospective cohort study with expert pathologist review, Lamba et al9 observed a considerably lower rate of 0.9%, noting that expert re-review reclassified one-third of initially reported SSLd as either traditional serrated adenoma (TSA) or collision-type lesions. Significant heterogeneity has been reported in the SSL detection rate (SSLDR), with estimates ranging from 0.6% to over 20% across populations and endoscopists.10, 11, 12 This variation is attributable to operator-dependent factors, differences in bowel preparation quality, withdrawal time, and interobserver variability in pathological evaluation. Colonoscopy series with a low SSLDR are particularly at risk of detection bias, as many SSLs may not have been identified, and those that were detected may have been disproportionately larger, more atypical, or more likely to harbor dysplasia. Consequently, accurate characterization of SSLd epidemiology requires data generated in the context of a high SSLDR. Data on the anatomical distribution of SSLd are limited. SSLs are predominantly proximal lesions, with the majority located in the cecum, ascending colon, and transverse colon.3,7 Existing literature generally reports a similar proximal predominance of SSLd; however, few studies have examined whether the rate of dysplasia within SSLs varies by specific anatomical site once the overall distribution of SSLs is accounted for. Understanding site-specific dysplasia rates is relevant to clinical practice, as it may inform endoscopic surveillance strategies and highlight whether certain colonic segments warrant particularly careful inspection. Several risk factors for SSLd have been identified. Lamba et al9 found that older age and a greater number of synchronous SSLs per patient were independent predictors of SSLd in multivariate analysis. Bettington et al6 similarly reported that patients with SSLd were significantly older than those with non-dysplastic SSLs. The association between synchronous SSL burden and dysplasia is particularly noteworthy, as it may reflect an inherent predisposition to molecular progression along the serrated pathway in certain individuals.13 The present study aimed to determine the prevalence and anatomical distribution of dysplasia in SSLs identified from a single-endoscopist practice at a regional Australian hospital over a 7-year period, utilizing a systematically standardized pathology database and histopathology meeting review of all suspected SSLd. We sought to assess whether dysplasia rates varied by colonic location and to examine the association between synchronous SSL burden and the presence of dysplasia. Methods Study Design and Data Source A retrospective cohort study was conducted using a pathology database of all serrated lesion specimens submitted to Douglass Hanly Moir Pathology by a single endoscopist (S.K.) at Port Macquarie, New South Wales, Australia. Port Macquarie is a regional coastal town approximately 400 km north of Sydney, with a catchment population of about 300,000. The study period spanned January 2019 to December 2025. Each record represented a single pathology specimen and included the collection date, episode number, anatomical site, pathology diagnosis, and the full pathology report text. Data Standardization Pathology terminology was systematically standardized using automated text parsing. All variants of SSL nomenclature (including sessile serrated adenoma, sessile serrated polyp, sessile serrated adenoma/polyp, and serrated adenoma/polyp) were unified under the term “sessile serrated lesion” in accordance with the 2019 World Health Organization Classification of Tumours of the Digestive System.14 Anatomical site names were mapped to standardized colonic locations (cecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, rectosigmoid, and rectum). Specimens with pathology diagnoses that did not correspond to a serrated lesion (eg, tubular adenoma, hyperplastic polyp, normal mucosa) were excluded from analysis. Dysplasia Classification Dysplasia was classified as a binary variable (present or absent). The full pathology report text for each specimen was parsed to identify dysplasia specifically attributable to the SSL component. The parsing algorithm identified numbered specimen items in each report and matched them to the anatomical site in the corresponding database record. Dysplasia was counted only when the report text directly linked it to the serrated lesion, using phrases such as “sessile serrated adenoma with dysplasia,” “sessile serrated polyp with low-grade dysplasia,” or equivalent constructions. Dysplasia in co-existing conventional adenomas within the same specimen (eg, “tubular adenoma with low-grade dysplasia” alongside a separate SSL diagnosis) was not counted as SSL dysplasia. Reports containing the phrase “negative for dysplasia” in the context of the serrated lesion were classified as non-dysplastic. Pathological Review As standard practice at our institution, all colonoscopy polypectomy specimens are reported by general pathologists at Douglass Hanly Moir Pathology. During the study period, all specimens initially identified as SSLd on routine pathology reporting were presented at the institutional histopathology meeting for review and discussion. At these meetings, the original pathology slides were reviewed, and the diagnosis was confirmed or reclassified based on consensus assessment. SSLd shares histological features with TSA, conventional adenoma (CA), and conventional adenoma with a serrated growth pattern;9,15 therefore, careful histological assessment is required for accurate diagnosis. Only SSLd cases confirmed after histopathology meeting review were included in the final confirmed SSLd count, though both initial and confirmed data are presented for transparency. Anatomical Classification SSLs were classified by anatomical site and by colonic segment. The proximal colon was defined as the cecum to the splenic flexure inclusive; the distal colon comprised the descending colon to the rectum. This definition is consistent with embryological derivation (midgut vs hindgut) and aligns with established convention in the serrated neoplasia literature. Specimens for which the anatomical site could not be determined from the database record (eg, specimens recorded as “colon” without a specific segment) were classified as unspecified, excluded from site-specific analyses, but retained in overall prevalence calculations. Statistical Analysis Descriptive statistics are presented as counts and percentages for categorical variables, and as means with standard deviations or medians with interquartile ranges (IQRs) for continuous variables, as appropriate. Differences in dysplasia rates between anatomical sites and between proximal and distal segments were assessed using the chi-squared test or Fisher's exact test when expected cell counts were less than 5. The association between synchronous SSL count per episode and the presence of dysplasia was assessed using the Mann-Whitney U test. A 2-sided P value of <.05 was considered statistically significant. Exact binomial (Clopper-Pearson) confidence intervals (CIs) were calculated for overall prevalence estimates. Analyses were performed using R (v 4.5.2). Ethics Ethics approval for this study was granted by the Social Sciences and Humanities Inter-divisional Research Ethics Committee at the University of Oxford (Reference Number: EQ C1A 19052). This study was carried out in accordance with the ethical principles described in the Declaration of Helsinki. Results Study Population A total of 3694 pathology records were identified in the database over the 7-year study period. After excluding 124 records (3.4%) in which the pathology diagnosis field did not correspond to an SSL, 3570 SSL specimens from 2701 unique colonoscopy episodes were included in the analysis. The study period spanned from January 8, 2019, to December 22, 2025. The annual SSL volume was consistent, ranging from 460 to 570 specimens per year (Table 1). The mean number of SSLs per episode was 1.3 (median 1; IQR 1–1; range 1–12). Procedure-level bowel preparation quality was not recorded in the pathology database. However, all colonoscopies were performed by a single endoscopist using split-dose bowel preparation in accordance with contemporary quality standards. This endoscopist has a previously reported high SSLDR,16 a quality indicator that depends on adequate mucosal visualization.Table 1Annual Distribution of SSLs and Initial Dysplasia RatesYearTotal SSLsEpisodesDysplasia (n)Dysplasia (%)2019522406101.922020513357112.142021518391163.09202247234861.272023515390163.112024460378316.742025570431122.11Total357027011022.86Dysplasia counts reflect initial pathology reporting. After histopathology meeting review, the confirmed total was 93 SSLd (2.61%).Total count in bold. Table 1Annual Distribution of SSLs and Initial Dysplasia RatesYearTotal SSLsEpisodesDysplasia (n)Dysplasia (%)2019522406101.922020513357112.142021518391163.09202247234861.272023515390163.112024460378316.742025570431122.11Total357027011022.86Dysplasia counts reflect initial pathology reporting. After histopathology meeting review, the confirmed total was 93 SSLd (2.61%).Total count in bold. Annual Distribution of SSLs and Initial Dysplasia Rates Dysplasia counts reflect initial pathology reporting. After histopathology meeting review, the confirmed total was 93 SSLd (2.61%). Total count in bold. Prevalence of Dysplasia and Pathological Review On initial pathology reporting, 102 SSLs were identified as harboring cytological dysplasia (2.86%). All 102 specimens were subsequently presented at the institutional histopathology meeting for review. After re-evaluation, 9 specimens (8.8%) were reclassified: 3 were determined to be collision-type lesions consisting of separate tubular adenoma and SSL (where the dysplasia was attributable to the adenomatous component rather than the SSL), 3 were found to have no dysplasia on review, 2 were reclassified as TSA, and 1 was reclassified as a conventional adenoma with a serrated growth pattern. The reclassified specimens were located in the ascending colon (4), transverse colon (3), and sigmoid colon (2). After this review process, 93 SSLds were confirmed (2.61%; exact binomial 95% CI: 2.12–3.19). The flow of specimens through the histopathology meeting review, including the reclassification of the 9 specimens by diagnostic category, is summarized in Figure 1.Figure 1Flow of suspected SSLd through histopathology meeting review. Flow of suspected SSLd through histopathology meeting review. On a per-episode basis, 82 of 2701 episodes (3.04%) contained at least one dysplastic SSL on initial reporting. Twelve episodes (14.6% of all dysplasia-containing episodes) harbored multiple synchronous SSLd within the same procedure, with the number of concurrent dysplastic SSLs ranging from 2 to 4 per episode. Anatomical Distribution The anatomical distribution of all SSLs and dysplastic SSLs (both initial and confirmed) is presented in Table 2. The most common site for SSLs overall was the transverse colon (1035; 29.0%), followed by the ascending colon (652; 18.3%), sigmoid colon (495; 13.9%), and cecum (377; 10.6%). The majority of SSLs (2114; 59.2%) were located in the proximal colon (cecum to splenic flexure), while 824 (23.1%) were distal and 632 (17.7%) were at unspecified sites.Table 2Anatomical Distribution of SSLs and Prevalence of Dysplasia (Initial and Confirmed After Review)SiteSSLs (n)% of totalInitial SSLd (n)Initial rate (%)Reclass.Confirmed SSLd (n)Confirmed rate (%)Cecum37710.692.39092.39Ascending65218.3203.074162.45Hepatic flex.491.400.00000.00Transverse103529.0302.903272.61Splenic flex.10.000.00000.00Descending2156.073.26073.26Sigmoid49513.9183.642163.23Rectosigmoid70.2114.290114.29Rectum1073.010.93010.93Proximal211459.2592.797522.46Distal82423.1273.282253.03All specified293882.3862.939772.62Proximal: cecum to splenic flexure. Distal: descending colon to rectum. Unspecified sites (n = 632, including 16 confirmed SSLd) excluded from rows above. Reclass. = specimens reclassified at histopathology meeting (3 collision-type TA/SSL, 3 no dysplasia, 2 TSA, 1 conventional adenoma with serrated growth pattern). Overall confirmed SSLd: 93/3570 (2.61%).Breakdown of proximal and distal in bold. Table 2Anatomical Distribution of SSLs and Prevalence of Dysplasia (Initial and Confirmed After Review)SiteSSLs (n)% of totalInitial SSLd (n)Initial rate (%)Reclass.Confirmed SSLd (n)Confirmed rate (%)Cecum37710.692.39092.39Ascending65218.3203.074162.45Hepatic flex.491.400.00000.00Transverse103529.0302.903272.61Splenic flex.10.000.00000.00Descending2156.073.26073.26Sigmoid49513.9183.642163.23Rectosigmoid70.2114.290114.29Rectum1073.010.93010.93Proximal211459.2592.797522.46Distal82423.1273.282253.03All specified293882.3862.939772.62Proximal: cecum to splenic flexure. Distal: descending colon to rectum. Unspecified sites (n = 632, including 16 confirmed SSLd) excluded from rows above. Reclass. = specimens reclassified at histopathology meeting (3 collision-type TA/SSL, 3 no dysplasia, 2 TSA, 1 conventional adenoma with serrated growth pattern). Overall confirmed SSLd: 93/3570 (2.61%).Breakdown of proximal and distal in bold. Anatomical Distribution of SSLs and Prevalence of Dysplasia (Initial and Confirmed After Review) Proximal: cecum to splenic flexure. Distal: descending colon to rectum. Unspecified sites (n = 632, including 16 confirmed SSLd) excluded from rows above. Reclass. = specimens reclassified at histopathology meeting (3 collision-type TA/SSL, 3 no dysplasia, 2 TSA, 1 conventional adenoma with serrated growth pattern). Overall confirmed SSLd: 93/3570 (2.61%). Breakdown of proximal and distal in bold. Dysplasia by Anatomical Site After histopathology meeting review, confirmed dysplasia rates by individual anatomical site ranged from 0% at the hepatic flexure (0/49) and splenic flexure (0/1) to 3.26% at the descending colon (7/215). Among sites with substantial numbers, the highest confirmed dysplasia rate was observed in the descending colon (3.26%) and sigmoid colon (3.23%; 16/495), followed by the transverse colon (2.61%; 27/1035), ascending colon (2.45%; 16/652), and cecum (2.39%; 9/377). No individual site demonstrated a statistically significant difference in confirmed dysplasia rate compared to the remaining sites when assessed by chi-squared or Fisher's exact test (all P > .05; Table 2). Proximal vs Distal Distribution The confirmed dysplasia rate did not differ significantly between the proximal colon (2.46%; 52/2114) and distal colon (3.03%; 25/824) (chi-squared test; P = .46). Of the 77 confirmed dysplastic SSLs with a specified location, 52 (67.5%) were located in the proximal colon and 25 (32.5%) in the distal colon. This distribution of SSLd closely mirrors the overall anatomical distribution of SSLs, consistent with a uniform dysplasia rate across colonic segments. Association With Synchronous Sessile Serrated Lesions Episodes containing at least one dysplastic SSL had a higher mean number of synchronous SSLs per episode (1.6; median 1; IQR, 1–2) compared to episodes without dysplasia (1.3; median 1; IQR 1–1; Mann-Whitney U test, P = .005). Twelve of 82 dysplasia-containing episodes (14.6%) harbored 2 or more synchronous SSLds within the same procedure. In these 12 episodes, the number of concurrent dysplastic SSLs ranged from 2 to 4, and in the majority of cases all SSLs within the episode were dysplastic, suggesting a field effect of dysplastic change in certain individuals. Temporal Trends The annual distribution of SSLs and initial dysplasia rates is shown in Table 1 and Figure 2. Annual SSL volumes ranged from 460 to 570, with corresponding episode counts of 348–431 per year. The initial dysplasia rate fluctuated across the study period, ranging from 1.27% in 2022 to 6.74% in 2024. There was no consistent temporal trend.Figure 2Annual distribution of SSLs and dysplasia. Annual distribution of SSLs and dysplasia. Discussion In this single-endoscopist pathology cohort spanning 7 years and comprising 3570 SSLs, 2.61% of SSLs harbored confirmed cytological dysplasia after histopathology meeting review. Dysplasia was distributed throughout the colorectum, with no significant difference between proximal and distal sites, and no individual anatomical site showed a significantly elevated dysplasia rate. The presence of multiple synchronous SSLs within an episode was associated with dysplasia, consistent with findings from the prospective cohort reported by Lamba et al.9 The confirmed SSLd rate of 2.61% in the present study is higher than the 0.9% reported by Lamba et al9 in their prospective cohort from the Royal Brisbane and Women's Hospital but falls within the 2%–5% range consistently reported in large retrospective pathology series by Bettington et al6 and Yang et al7 A recent nationwide Dutch pathology databank study by Angerilli et al17 reported dysplasia in 9.4% of 186,427 SSLs, a substantially higher frequency that likely reflects differences in case ascertainment and diagnostic thresholds across very large unselected pathology databases. Comparable rates have been reported in the Dutch national fecal immunochemical test-based screening program, where van Roermund et al18 found dysplasia in 9.1% of 76,771 SSLs, corresponding to an SSLd prevalence of 1.1% among screenees. The incorporation of a histopathology meeting review in the present study provides an important intermediate step between unreviewed community pathology reports and the formal blinded dual-expert-pathologist review employed by Lamba et al.9 In their study, 12 of 36 initially reported SSLd (33.3%) were reclassified, with the most common alternative diagnoses being TSA (8 cases) and collision-type polyps (4 cases). In the present cohort, 9 of 102 initially reported SSLd (8.8%) were reclassified, with a strikingly similar pattern of alternative diagnoses: collision-type lesions of separate TA and SSL (3 cases), absence of dysplasia on review (3 cases), TSA (2 cases), and conventional adenoma with a serrated growth pattern (1 case). Beyond the comparison with Lamba et al,9 the present findings are consistent with the broader retrospective literature on SSLd. Yang et al 7 examined the anatomic distribution of sessile serrated adenoma/polyps with and without cytological dysplasia and similarly observed that dysplastic lesions occurred throughout the colorectum rather than being confined to a single segment. In one of the largest series to date, Lash et al8 reported dysplasia or carcinoma in only a small minority of SSLs among 2139 patients, reinforcing that overt dysplasia remains an uncommon finding even in large unselected cohorts. Bettington et al6 characterized the clinicopathological and molecular features of SSLs with dysplasia, demonstrating an association with older patient age and with loss of MLH1 expression, while Liu et al15 described the morphological heterogeneity of dysplasia within SSLs and its correlation with MLH1 immunohistochemistry, underscoring the diagnostic challenge that motivated the histopathology review process used here. Endoscopically focused studies, including the prospective multicenter analysis of large SSLs by Burgess et al19 and the work of Sano et al,20 have identified increasing lesion size and specific surface features as predictors of cytological dysplasia or cancer. Taken together, these studies indicate that dysplasia within SSLs is uncommon, lesion-intrinsic, and strongly influenced by lesion size and molecular progression, observations that complement the anatomical and synchronous-burden findings of the present cohort. The considerably lower reclassification rate in the present study (8.8% vs 33.3%) is noteworthy and may reflect several factors. First, the present study spans 2019–2025, during which pathologist awareness and familiarity with SSLd diagnostic criteria have likely improved compared to the 2018–2020 period of the Lamba et al9 cohort. Second, the automated text-parsing algorithm used to identify SSLd from pathology reports applied strict attribution rules, requiring that dysplasia be explicitly linked to the serrated lesion diagnosis in the report text. This may have excluded some ambiguous cases that would have been captured by manual chart review. Third, differences in institutional reporting thresholds and pathologist experience between the 2 settings may contribute. Regardless of the specific mechanism, the finding that the pattern of reclassification (collision lesions, TSA, and absence of dysplasia) is consistent across both studies reinforces the importance of histopathological review for all suspected SSLd, as the clinical significance and surveillance implications differ substantially between these diagnoses.21,22 Reassuringly, recent data suggest that the reproducibility of SSLd diagnosis is improving. In a national audit, Angerilli et al17 observed diagnostic discrepancies in only 11% of SSLd cases, comparable to the 8.8% reclassification rate in the present cohort and consistent with overall good interobserver agreement. That study also identified MLH1 immunohistochemistry as the only ancillary marker of robust value for identifying dysplasia that does not meet morphological criteria, although it was used by only 20% of laboratories and is recommended only in selected cases.17 The persistent diagnostic overlap between SSLd and TSA is well recognized; as reviewed by Rosty et al,23 TSAs may arise from a background SSL, and their evolving morphological classification and terminology remain a source of interobserver variability, reinforcing the value of specialist or consensus review for these lesions. The finding that confirmed dysplasia rates were comparable across colonic segments is a notable observation that has not been the primary focus of previous studies. In the Lamba et al cohort,9 19 of 24 confirmed SSLd (79.2%) were located proximal to the splenic flexure, broadly consistent with the known proximal predominance of SSLs. However, their study did not directly compare the rate of dysplasia within proximal vs distal SSLs. In the present study, the confirmed dysplasia rates were 2.46% (proximal) and 3.03% (distal) with no statistically significant difference (P = .46). This suggests that once an SSL is established, the probability of acquiring cytological dysplasia may be independent of its colonic location. From a clinical perspective, this finding reinforces the importance of thorough inspection throughout the entire colon, including distal segments, for patients with serrated lesions. The association between a higher synchronous SSL count per episode and the presence of dysplasia is concordant with the multivariate findings of Lamba et al,9 who reported the total number of SSLs per patient as an independent predictor of SSLd (odds ratio: 1.12; 95% CI: 1.02–1.23; P = .015). In the present study, episodes containing dysplastic SSLs had a significantly higher mean SSL count compared to non-dysplastic episodes (P = .005). This finding supports the hypothesis that patients with a higher SSL burden may have a greater inherent propensity for molecular progression along the serrated pathway, possibly related to enhanced CpG island methylation or other epigenetic mechanisms. It also aligns with the well-recognized association between SSLd and serrated polyposis syndrome, where patients carry a high SSL burden and are at elevated CRC risk.24 Lamba et al9 found that 30% (6/20) of patients with SSLd met diagnostic criteria for serrated polyposis syndrome, further supporting this relationship. The finding that 14.6% of dysplasia-containing episodes harbored multiple synchronous SSLd is notable. Lamba et al9 similarly found that 35% of patients with SSLd had synchronous or metachronous dysplastic lesions during follow-up. This clustering of SSLd within certain individuals supports the concept of a field effect, whereby patients predisposed to SSL development may also be predisposed to dysplastic progression across multiple lesions simultaneously. From a surveillance perspective, the detection of one SSLd at colonoscopy should prompt particularly careful evaluation of all remaining colonic segments for additional dysplastic or precancerous lesions. The temporal variation in annual initial dysplasia rates, ranging from 1.27% in 2022 to 6.74% in 2024, warrants comment. The notably elevated 2024 rate was not accompanied by a corresponding increase in total SSL volume and may reflect changes in pathologist reporting thresholds, case-mix variation, or stochastic fluctuations in a relatively uncommon diagnosis. In this regard, van Roermund et al18 observed that the dysplasia rate within SSLs in the Dutch screening program declined over time (from 17.5% in 2014 to 6.6% in 2023) as overall SSL detection increased, suggesting that rising detection of small, non-dysplastic SSLs may dilute the apparent dysplasia rate. More broadly, this fluctuation likely reflects several interrelated factors rather than genuine biological variation. Changes in pathology reporting practices, individual pathologist interpretation, and evolving awareness of SSLd among reporting pathologists may all contribute. This temporal variability further underscores the value of the histopathology meeting review process employed in this study, which provides a consistent standard of diagnostic evaluation across the study period. Future Directions Several future directions arise from this work. Prospective, multicenter studies that capture patient-level characteristics (age, sex, smoking status, prior adenoma history, and body mass index), lesion size, and structured bowel preparation data would allow these determinants of dysplasia to be modeled directly and address the principal limitations of retrospective pathology cohorts. Linking serrated lesion pathology to long-term colorectal and post-colonoscopy CRC outcomes would further clarify the clinical significance of site-specific and synchronous SSLd. In parallel, artificial intelligence is likely to contribute substantially to this field. Computer-aided detection systems have been shown to improve adenoma detection in randomized trials and meta-analyses,25 and emerging data suggest a benefit for serrated lesion detection,26 although the magnitude of benefit varies by system. Beyond detection, computer-aided diagnosis and computational pathology hold promise for standardizing the recognition of dysplasia within serrated lesions, potentially reducing the interobserver variability that necessitates the histopathology review described here. Rigorous prospective evaluation of these tools in both screening and surveillance settings is an important priority. Strengths The principal strengths of this study include the large sample size (3570 SSLs), the 7-year study duration, which provides temporal breadth, the single-endoscopist design, which ensures consistency in lesion detection and removal techniques, and the systematic approach to terminology standardization and dysplasia attribution. Importantly, the incorporation of histopathology meeting review for all suspected SSLd provides diagnostic validation beyond routine community pathology reporting, a feature unique among large retrospective SSL cohort studies. The ability to present both initial and confirmed dysplasia data, stratified by anatomical site, allows transparent assessment of the impact of pathological review. The endoscopist (S.K.) has a previously reported high SSLDR,16 minimizing detection bias that affects many existing studies. Limitations Several limitations should be acknowledged. First, although all suspected SSLd were reviewed at the histopathology meeting, this process did not involve formal blinded re-evaluation by 2 independent specialist gastrointestinal pathologists, as used by Lamba et al.9 The histopathology meeting review nonetheless provides a meaningful quality-assurance step. Second, the database captures only serrated lesion specimens and excludes all polyps removed at each colonoscopy, precluding a complete assessment of synchronous adenoma burden, overall polyp detection rates, or the total colonoscopy denominator needed to calculate a formal SSLDR. Third, patient-level demographic data (age, sex, smoking history, and body mass index) were not available in the pathology database, preventing analysis of these variables as predictors of dysplasia and precluding comparison of patient characteristics between SSLd and non-dysplastic SSL groups. Fourth, polyp size data were not available in a structured format, preventing assessment of the well-described association between SSL size and dysplasia risk. Notably, although dysplasia is more frequent in larger lesions, van Roermund et al18 found that 64% of dysplastic SSLs were <10 mm, indicating that the lack of size data does not preclude a meaningful estimate of dysplasia prevalence and underscoring the importance of carefully evaluating small serrated polyps. Fifth, the episode number serves as a proxy for individual encounters but does not permit reliable longitudinal patient-level analysis of metachronous lesions across multiple procedures, as individual patients may be represented by multiple episode numbers over the 7-year study period. Conclusion In a large, single-endoscopist pathology cohort spanning 7 years, with histopathology meeting review of all suspected SSLd, 2.61% of SSLs harbored confirmed cytological dysplasia. The reclassification rate of 8.8% was lower than the 33.3% observed in a prospective study with formal dual-expert pathologist review, but the pattern of reclassification was similar, with collision-type lesions, TSA, conventional adenoma with a serrated growth pattern, and absence of dysplasia as the most common alternative diagnoses. Dysplasia was distributed uniformly throughout the colorectum, with no significant proximal-distal predilection (2.46% vs 3.03%; P = .46), and no individual anatomical site showed a significantly different dysplasia rate. A higher synchronous SSL burden was associated with the presence of dysplasia. These findings contribute to the understanding of SSLd epidemiology and support the recommendation for careful inspection at all colonic sites during colonoscopy for patients with serrated lesions. A histopathology meeting review of all suspected SSLd is recommended to ensure diagnostic accuracy and appropriate risk stratification for surveillance.